Skip to main content

Table 2 Univariate and multivariate cox proportional hazards regression analysis for recurrence free survival

From: Impact of molecular surgical margin analysis on the prediction of pancreatic cancer recurrences after pancreaticoduodenectomy

  RFS
Univariate analysis Multivariate analysis
HR 95% CI p value HR 95% CI p value
Age (≥ 66 vs. < 66) 1.489 0.620–3.576 0.373    
Gender (Male vs. female) 0.559 0.235–1.331 0.189    
Tumor size at diagnosis (> 2 cm vs. ≤ 2 cm) 0.835 0.322–2.170 0.712    
NAT (yes vs. no) 0.952 0.400–2.269 0.912    
Radiation (yes vs no) 0.365 0.048–2.755 0.329    
CA 19-9 (> 37 U/ml vs. ≤ 37 U/ml) 1.780 0.717–4.417 0.214    
DUPAN-2 (> 150 U/ml vs. ≤ 150 U/ml) 2.201 0.931–5.204 0.073    
Pathological surgical margin (positive vs. negative) 0.762 0.295–1.969 0.575    
Pathological surgical margin (≤ 1 mm vs. > 1 mm) 0.686 0.287–1.641 0.397    
Molecular surgical margin (positive vs. negative) 3.989 1.569–10.14 0.004 3.522 1.352–9.179 0.010
CY (positive vs. negative) 0.767 0.177–3.320 0.722    
n (positive vs. negative) 0.275 0.037–2.048 0.207    
ly (positive vs. negative) 2.706 0.986–7.425 0.053    
v (positive vs. negative) 2.841 1.178–6.848 0.020 2.323 0.936–5.769 0.069
s (positive vs. negative) 1.672 0.558–5.012 0.359    
rp (positive vs. negative) 1.876 0.630–5.590 0.259    
ch (positive vs. negative) 1.735 0.718–4.196 0.221    
du (positive vs. negative) 1.249 0.525–2.972 0.615    
pv (positive vs. negative) 0.876 0.351–2.188 0.777    
  1. Bold indicates P < 0.05
  2. NAT; neoadjuvant chemotherapy, CY; Peritoneal washing cytology, n; Lymph node metastasis, ly; Lymphatic invasion, v; Venous invasion, s; Serosal side of the anterior pancreatic invasion, rp; Retropancreatic tissue invasion, ch; Bile duct invasion, du; Duodenal invasion, pv; Portal vein system invasion